Orforglipron vs Tirzepatide
A side-by-side research comparison of Orforglipron and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Orforglipron | Tirzepatide |
|---|---|---|
| Full name | Orforglipron (Oral Non-Peptide GLP-1 Agonist) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | FDA Approved |
| Mechanism | Small molecule agonist of GLP-1 receptors that mimics native GLP-1 binding without requiring peptide structure. Achieves full receptor activation with standard oral bioavailability. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | ~550 Da | 4,814 Da |
| Half-life | 25-60 hours | 5 days (120 hours) |
| Bioavailability | Moderate-High (oral) | High (SubQ ~80%) |
| Typical dose | 12-45 mg | 2.5 mg → titrate up to 15 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral | Subcutaneous injection |
Orforglipron reported benefits
- Oral administration (no injection)
- No fasting requirement
- Significant weight loss (8-14%)
- Small molecule stability
- Lower manufacturing cost potential
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.